Alerta

用于利用质膜锚定蛋白酶的系统和方法

Resumen de: WO2025059015A1

Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.

美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用

Resumen de: CN122410031A

本发明提供了美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用，属于生物医药技术领域。本发明发现GluN2A蛋白是小细胞肺癌不良预后及靶向干预的重要分子标志物。另外，本发明发现美金刚、其衍生物或药用盐能够以剂量依赖的方式显著抑制小细胞肺癌细胞的活力、克隆形成能力、DNA复制活性及迁移能力，并有效破坏3D肿瘤球体的形成、诱导肿瘤细胞死亡，显著减小了小细胞肺癌异种移植瘤的体积和重量。本发明提供的伴随诊断与靶向用药策略，克服了传统非选择性用药的盲目性，为现有小细胞肺癌的治疗提供了新的药物解决方案。

诊断剂

Resumen de: WO2025120152A1

The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET) -associated pathologies.

BILIARY TRACT CANCER TREATMENT WITH ANTI-CLAUDIN 18.2 ADC

Resumen de: US20260199509A1

Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.

MEDICAL DIAGNOSIS, PROGNOSIS AND PREDICTION OF TREATMENT USING MULTIPLEXED SIGNATURES

Resumen de: WO2026151932A1

The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.

NANOBODY AGAINST γ-AMINOBUTYRIC ACID TYPE B RECEPTOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026149125A1

Provided are a nanobody against γ-aminobutyric acid type B receptor, and a preparation method therefor and the use thereof. The nanobody can specifically recognize and bind to the γ-aminobutyric acid type B receptor, exhibits a good affinity therefor, and can be used in the preparation of a product for diagnosing, preventing or treating diseases or conditions associated with the γ-aminobutyric acid type B receptor, or for detecting the presence or level of the γ-aminobutyric acid type B receptor in a sample.

POTENCY ASSAY FOR PHARMACEUTICAL PRODUCTS

Resumen de: US20260202397A1

0000 The present invention describes a method for assessing the potency of a pharmaceutical product assumed to be effective in treating a disorder, preferably a genetic disorder or a non-genetic disorder, wherein the disorder results in an impaired functionality of a physiological bodily function of a subject having the disorder, wherein the method comprises: (i) incubating an engineered tissue with the pharmaceutical product, wherein the engineered tissue is or has been modified to be representative for the disorder; (ii) determining at least one physical parameter of the engineered tissue resulting from step (i), wherein the physical parameter is a measure of the functionality of the physiological bodily function, and (iii) determining whether a value of the at least one physical parameter determined in step (ii) meets a predetermined threshold of said physical parameter, which determines whether the pharmaceutical product has potency, wherein, if said value of the at least one physical parameter exceeds the predetermined threshold, potency of the pharmaceutical product is indicated for treating the disorder by at least partially restoring the functionality of the physiological bodily function.

LIGANDS SPECIFIC FOR ASCT1

Resumen de: US20260200988A1

Polypeptides capable of specifically recognizing and binding to the neutral amino acid transporter ASCT1/SLC1A4, while not binding to the related neutral amino acid transporter ASCT2/SLC1A5. Also, both in vitro and in vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.

DE NOVO DESIGNED PROTEIN BINDERS TO NATIVE FLEXIBLE HELICAL PEPTIDES

Resumen de: US20260201015A1

0000 Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods for use of the polypeptides in detecting binding of the target and correlating binding to the target with a disease state.

METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY ADVERSE EVENTS BASED ON IMMUNE CELL POPULATIONS

Resumen de: US20260202406A1

0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.

MULTIPLE SFLT-1 MEASUREMENTS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA

Resumen de: US20260202422A1

The invention relates to a method of treatment for early onset preeclampsia in a pregnant subject, including determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The invention further relates to the combined measurement of sFlt-1 and PlGF, The invention relates further to a kit for carrying out the method of the invention, including detection reagents for determining the level sFlt-1 or fragment(s) thereof, and optionally for determining the level of at least one additional biomarker, in a sample from a subject.

METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING TRIPLE NEGATIVE BREAST CANCER

Resumen de: US20260201473A1

0000 Biomarkers that can be used for the detection or diagnosis of disease states, preferably cancer (e.g., triple negative breast cancer (TNBC)) disease states, to the prediction of disease prognosis and/or a treatment outcome, to the identification of a treatment regimen for cancer (e.g., TNBC), and/or to indicate the responsiveness to the treatment regimen for cancer (e.g., TNBC) in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining cancer (e.g., TNBC) disease states and/or identification of treatment regimens for the cancer (e.g., TNBC) disease states.

β－カテニンデポの検出及び調節アッセイ

Resumen de: WO2025014769A1

The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.

ANTI-TAU MTBR ANTIBODIES AND METHODS TO DETECT CLEAVED FRAGMENTS OF TAU AND USES THEREOF

Resumen de: US20260201023A1

0000 Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.

PROTEIN ANTIGEN COMBINATION FOR ALZHEIMER'S DISEASE DETECTION AND USE

Resumen de: AU2024418168A1

A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.

Novel Molecules for Therapy and Diagnosis

Resumen de: US20260201026A1

0000 The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

EARLY DIAGNOSIS SYSTEM UTILIZING STANDARD DEVIATION AND AUTOCORRELATION OF DYNAMIC FLUORESCENT OR X-RAY

Resumen de: US20260202426A1

0000 The present disclosure relates to a method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or by using dynamic X-rays. A method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or labeling with a crystalline plane, according to an aspect, enables large-scale imaging and Z-axis imaging, and thus can be effectively used in the field of diagnosis.

ANTI-CD103 ANTIBODIES

Resumen de: US20260201041A1

0000 The present invention relates to anti-CD103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases.

COMPOUNDS FOR TAU PROTEIN DEGRADATION

Resumen de: US20260199318A1

Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasonmal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

METHOD OF PROVIDING EARLY INTERVENTION TO A NEWBORN OR INFANT WITH AUTISM SPECTRUM DISORDER

Resumen de: US20260202427A1

0000 Described is use of biomarkers found in maternal mid-gestation (MMG) and cord blood (CB) plasma for early identification of children with autism spectrum disorder (ASD) or at risk for ASD. Using these biomarkers, newborns and infants with ASD or at high risk of ASD can be identified and interventions for ASD, which have been shown to be effective early in life, can be provided to a child as young as a newborn.

FFA1 (GPR40) AS A THERAPEUTIC TARGET FOR NEURAL ANGIOGENESIS DISEASES OR DISORDERS

Resumen de: US20260199341A1

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

METHOD OF MANUFACTURING BIOSENSOR FOR DETECTING BIOMARKER OF ALZHEIMER'S DISEASE AND BIOSENSOR MANUFACTURED THEREFROM

Resumen de: US20260202374A1

The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.

A HETEROHYBRIDOMA-BASED METHOD OF GENERATING RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AND ANTIBODIES PRODUCED BY METHOD

Resumen de: US20260201046A1

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

METHODS FOR IDENTIFYING DISEASE-ASSOCIATED RNA AND RNA BINDING PROTEIN (RBP) INTERACTIONS FOR DIAGNOSIS AND TREATMENT SELECTION

Resumen de: AU2024395871A1

The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.

METHODS AND SYSTEMS FOR PREPARING AND ANALYZING SAMPLES FOR EXTRACELLULAR VESICLE BIOMARKERS ASSOCIATED WITH BRAIN-RELATED CONDITIONS OR DISORDERS

Nº publicación: WO2026151876A1 16/07/2026

Solicitante:

HEALIX CLINICAL LABORATORY LLC [DE]
HEALIX CLINICAL LABORATORY LLC

Resumen de: WO2026151876A1

Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.